Cargando…
Collecting patient preference information using a Clinical Data Research Network: demonstrating feasibility with idiopathic pulmonary fibrosis
Purpose: Rare diseases present challenges for accessing patient populations to conduct surveys. Clinical Data Research Networks (CDRNs) offer an opportunity to overcome those challenges by providing infrastructure for accessing patients and sharing data. This study aims to demonstrate the feasibilit...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529600/ https://www.ncbi.nlm.nih.gov/pubmed/31190761 http://dx.doi.org/10.2147/PPA.S201632 |
_version_ | 1783420432742875136 |
---|---|
author | Hollin, Ilene L Dimmock, Anne EF Bridges, John FP Danoff, Sonye K Bascom, Rebecca |
author_facet | Hollin, Ilene L Dimmock, Anne EF Bridges, John FP Danoff, Sonye K Bascom, Rebecca |
author_sort | Hollin, Ilene L |
collection | PubMed |
description | Purpose: Rare diseases present challenges for accessing patient populations to conduct surveys. Clinical Data Research Networks (CDRNs) offer an opportunity to overcome those challenges by providing infrastructure for accessing patients and sharing data. This study aims to demonstrate the feasibility of collecting patient preference information for a rare disease in a CDRN, using idiopathic pulmonary fibrosis as proof of concept. Patients and methods: Utilizing a cohort of idiopathic pulmonary fibrosis (IPF) patients across a CDRN, a discrete choice experiment was administered via electronic and paper methods to collect patient preference information about benefits and risks of two therapeutic options. Survey data were augmented with data from electronic health records and patient-reported outcome surveys. Results: Thirty-three patients completed the preference experiment. The amount of choice attributable to a benefit of slowing of decline in lung function was 36%. Improving efficacy in terms of lung function was 2.16 times as important as improving efficacy in terms of shortness of breath. In terms of side effects, decreasing risk of gastrointestinal problems was 2.6 times as important as decreasing risk of sun sensitivity and 2.4 times as important as decreasing risk of liver injury. In terms of benefit-risk trade-offs, improving efficacy in terms of lung function was 1.6 times as important as decreasing risk of gastrointestinal problems. Conclusion: This study used IPF as a proof of concept to demonstrate the feasibility of collecting patient preference information in a CDRN. The network was advantageous to the study of patient preferences. Future research should continue to explore pathways for the collection and use of patient preference information across networks. The power of consolidated collection efforts may lead to the ability to use preference data to inform decision-making at the regional, specialty, or individual encounter level. |
format | Online Article Text |
id | pubmed-6529600 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-65296002019-06-12 Collecting patient preference information using a Clinical Data Research Network: demonstrating feasibility with idiopathic pulmonary fibrosis Hollin, Ilene L Dimmock, Anne EF Bridges, John FP Danoff, Sonye K Bascom, Rebecca Patient Prefer Adherence Original Research Purpose: Rare diseases present challenges for accessing patient populations to conduct surveys. Clinical Data Research Networks (CDRNs) offer an opportunity to overcome those challenges by providing infrastructure for accessing patients and sharing data. This study aims to demonstrate the feasibility of collecting patient preference information for a rare disease in a CDRN, using idiopathic pulmonary fibrosis as proof of concept. Patients and methods: Utilizing a cohort of idiopathic pulmonary fibrosis (IPF) patients across a CDRN, a discrete choice experiment was administered via electronic and paper methods to collect patient preference information about benefits and risks of two therapeutic options. Survey data were augmented with data from electronic health records and patient-reported outcome surveys. Results: Thirty-three patients completed the preference experiment. The amount of choice attributable to a benefit of slowing of decline in lung function was 36%. Improving efficacy in terms of lung function was 2.16 times as important as improving efficacy in terms of shortness of breath. In terms of side effects, decreasing risk of gastrointestinal problems was 2.6 times as important as decreasing risk of sun sensitivity and 2.4 times as important as decreasing risk of liver injury. In terms of benefit-risk trade-offs, improving efficacy in terms of lung function was 1.6 times as important as decreasing risk of gastrointestinal problems. Conclusion: This study used IPF as a proof of concept to demonstrate the feasibility of collecting patient preference information in a CDRN. The network was advantageous to the study of patient preferences. Future research should continue to explore pathways for the collection and use of patient preference information across networks. The power of consolidated collection efforts may lead to the ability to use preference data to inform decision-making at the regional, specialty, or individual encounter level. Dove 2019-05-16 /pmc/articles/PMC6529600/ /pubmed/31190761 http://dx.doi.org/10.2147/PPA.S201632 Text en © 2019 Hollin et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Hollin, Ilene L Dimmock, Anne EF Bridges, John FP Danoff, Sonye K Bascom, Rebecca Collecting patient preference information using a Clinical Data Research Network: demonstrating feasibility with idiopathic pulmonary fibrosis |
title | Collecting patient preference information using a Clinical Data Research Network: demonstrating feasibility with idiopathic pulmonary fibrosis |
title_full | Collecting patient preference information using a Clinical Data Research Network: demonstrating feasibility with idiopathic pulmonary fibrosis |
title_fullStr | Collecting patient preference information using a Clinical Data Research Network: demonstrating feasibility with idiopathic pulmonary fibrosis |
title_full_unstemmed | Collecting patient preference information using a Clinical Data Research Network: demonstrating feasibility with idiopathic pulmonary fibrosis |
title_short | Collecting patient preference information using a Clinical Data Research Network: demonstrating feasibility with idiopathic pulmonary fibrosis |
title_sort | collecting patient preference information using a clinical data research network: demonstrating feasibility with idiopathic pulmonary fibrosis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6529600/ https://www.ncbi.nlm.nih.gov/pubmed/31190761 http://dx.doi.org/10.2147/PPA.S201632 |
work_keys_str_mv | AT hollinilenel collectingpatientpreferenceinformationusingaclinicaldataresearchnetworkdemonstratingfeasibilitywithidiopathicpulmonaryfibrosis AT dimmockanneef collectingpatientpreferenceinformationusingaclinicaldataresearchnetworkdemonstratingfeasibilitywithidiopathicpulmonaryfibrosis AT bridgesjohnfp collectingpatientpreferenceinformationusingaclinicaldataresearchnetworkdemonstratingfeasibilitywithidiopathicpulmonaryfibrosis AT danoffsonyek collectingpatientpreferenceinformationusingaclinicaldataresearchnetworkdemonstratingfeasibilitywithidiopathicpulmonaryfibrosis AT bascomrebecca collectingpatientpreferenceinformationusingaclinicaldataresearchnetworkdemonstratingfeasibilitywithidiopathicpulmonaryfibrosis |